Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Rosmorduc

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Gastroenterologie Clinique Et Biologique|July 16, 2010
Antiangiogenic therapies in portal hypertension: a breakthrough in hepatologyO Rosmorduc
Gastroenterologie Clinique Et Biologique|March 27, 2009
[Hepatocellular carcinoma management in the era of sorafenib]O Rosmorduc
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Targeted HCC therapies: the door has been opened!]O Rosmorduc, L Fartoux
Clinics and Research in Hepatology and Gastroenterology|February 14, 2012
HCC and NASH: how strong is the clinical demonstration?O Rosmorduc, L Fartoux
Annals of Internal Medicine|October 24, 1998
Hepatotoxicity associated with ritonavirO Picard, O Rosmorduc, J Cabane
Gastroenterologie Clinique Et Biologique|June 12, 2010
The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adultsR Poupon, L Arrive, O Rosmorduc
Gastroenterology|April 21, 2001
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasisO Rosmorduc, B Hermelin, R Poupon
Journees Annuelles De Diabetologie De L'Hotel-Dieu|January 15, 2003
[Molecular genetics of hemochromatosis]O Rosmorduc, B Hermelin, R Poupon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-upC Verslype, O Rosmorduc, P Rougier, et al.
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]V Boige, J-C Barbare, O Rosmorduc, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Gastroenterologie Clinique Et Biologique|July 16, 2010
Antiangiogenic therapies in portal hypertension: a breakthrough in hepatologyO Rosmorduc
Gastroenterologie Clinique Et Biologique|March 27, 2009
[Hepatocellular carcinoma management in the era of sorafenib]O Rosmorduc
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Targeted HCC therapies: the door has been opened!]O Rosmorduc, L Fartoux
Clinics and Research in Hepatology and Gastroenterology|February 14, 2012
HCC and NASH: how strong is the clinical demonstration?O Rosmorduc, L Fartoux
Annals of Internal Medicine|October 24, 1998
Hepatotoxicity associated with ritonavirO Picard, O Rosmorduc, J Cabane
Gastroenterologie Clinique Et Biologique|June 12, 2010
The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adultsR Poupon, L Arrive, O Rosmorduc
Gastroenterology|April 21, 2001
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasisO Rosmorduc, B Hermelin, R Poupon
Journees Annuelles De Diabetologie De L'Hotel-Dieu|January 15, 2003
[Molecular genetics of hemochromatosis]O Rosmorduc, B Hermelin, R Poupon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-upC Verslype, O Rosmorduc, P Rougier, et al.
Gastroenterologie Clinique Et Biologique|March 18, 2008
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]V Boige, J-C Barbare, O Rosmorduc, et al.
Pageof 4